Pierre Fabre’s involvement in neuropsychiatry dates from the late 1980s, with the development of a molecule from Pierre Fabre research registered to treat depression in Europe and fibromyalgia in the United States.


troubles-depressifs.jpgGlobal presence

Our presence in the field of major depressive disorders extends over 45 countries, including many European countries (Austria, Finland, France, Portugal, Russia, etc.), as well as Japan, the Middle East, in several Latin American countries (Argentina, Chile, Mexico).

In 2008, we signed a license agreement with the American pharmaceutical company Forest Laboratories, Inc. to develop an antidepressant using a molecule discovered by the Pierre Fabre research teams. In the wake of the Phase III studies, finalized in 2012, Forest began marketing it in the United States in January 2014 under the name of Fetzima (levomilnacipran).


douleurs.jpg3rd medicine approved for fibromyalgia in the US

Pierre Fabre research has discovered milnacipran, a molecule subsequently developed and marketed by Forest Laboratories, Inc. in the United States under the name of Savella (Milnacipran). In January 2009, the Food and Drug Administration approved Pierre Fabre's milnacipran in the treatment of fibromyalgia, making it the third medicine approved for this indication in the United States.

In November 2011, the Therapeutic Goods Administration (TGA), the Australian health authority, granted a Marketing Authorization to Pierre Fabre for this same molecule for the treatment of fibromyalgia under the name of Joncia (Milnacipran).

Fibromyalgia is a syndrome that mainly involves debilitating pain, chronic fatigue, and sleep disorders. It affects 2%-3% of the population, primarily women (80%).


neuropsychiatrie.jpgA long-term commitment

Our commitment to neuropsychiatry research aims to provide new therapeutic solutions in the medium-to-long term for the treatment of schizophrenia, bipolar disorders, neurodegenerative disorders, depressive disorders, and chronic pain.